Products for Research Use Only
RegisterLogin

SSR69071

CAT: 0804-HY-103445Size: 1 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-103445Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
SSR69071 is a potent, orally active and selective inhibitor of neutrophil elastase. SSR69071 reduces myocardial infarct size following ischemia-reperfusion injury[1]. SSR69071 displays a higher affinity for human elastase (Ki=0.0168 nM) than for rat (Ki=3 nM), mouse (Ki=1.8 nM), and rabbit (Ki= 58 nM) elastases[2].
CAS Number
344930-95-6
UNSPSC
12352005
Target
Elastase
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease
Applications
Neuroscience-Neuromodulation
Field of Research
Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/ssr69071.html
Purity
98.4
Solubility
DMSO : 52 mg/mL (ultrasonic; warming)
Smiles
O=C1C=C(OCN(C(C2=C3C=C(OC)C=C2C(C)C)=O)S3(=O)=O)N=C4N1C=CC=C4OCCN5CCCCC5
Molecular Formula
C27H32N4O7S
Molecular Weight
556.63
References & Citations
[1]Jean-Pierre Bidouard, et al. SSR69071, an elastase inhibitor, reduces myocardial infarct size following ischemia-reperfusion injury. Eur J Pharmacol. 2003 Feb 7;461 (1) :49-52.|[2]Zoltan Kapui, et al. Biochemical and pharmacological characterization of 2- (9- (2-piperidinoethoxy) -4-oxo-4H-pyrido[1,2-a]pyrimidin-2-yloxymethyl) -4- (1-methylethyl) -6-methoxy-1,2-benzisothiazol-3 (2H) -one-1,1-dioxide (SSR69071), a novel, orally active elastase inhibitor. J Pharmacol Exp Ther. 2003 May;305 (2) :451-9.|[3]Márton Varga, et al. A novel orally active inhibitor of HLE. Eur J Med Chem. 2003 Apr;38 (4) :421-5.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported

Popular Products